25 XP   0   0   10

Panacea Biotec Limited
Buy, Hold or Sell?

Let's analyse Panacea Biotec Limited together

PenkeI guess you are interested in Panacea Biotec Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Panacea Biotec Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Panacea Biotec Limited

I send you an email if I find something interesting about Panacea Biotec Limited.

Quick analysis of Panacea Biotec Limited (30 sec.)










What can you expect buying and holding a share of Panacea Biotec Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR137.16
Expected worth in 1 year
INR133.44
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
INR-3.72
Return On Investment
-2.5%

For what price can you sell your share?

Current Price per Share
INR146.50
Expected price per share
INR116.00 - INR169.70
How sure are you?
50%

1. Valuation of Panacea Biotec Limited (5 min.)




Live pricePrice per Share (EOD)

INR146.50

Intrinsic Value Per Share

INR-1,059.40 - INR-83.30

Total Value Per Share

INR-922.24 - INR53.86

2. Growth of Panacea Biotec Limited (5 min.)




Is Panacea Biotec Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$100.8m$101.4m-$684.1k-0.7%

How much money is Panacea Biotec Limited making?

Current yearPrevious yearGrowGrow %
Making money-$4m$129.3m-$133.4m-3,295.0%
Net Profit Margin-7.3%163.6%--

How much money comes from the company's main activities?

3. Financial Health of Panacea Biotec Limited (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#373 / 1010

Most Revenue
#146 / 1010

Most Profit
#391 / 1010

Most Efficient
#457 / 1010

What can you expect buying and holding a share of Panacea Biotec Limited? (5 min.)

Welcome investor! Panacea Biotec Limited's management wants to use your money to grow the business. In return you get a share of Panacea Biotec Limited.

What can you expect buying and holding a share of Panacea Biotec Limited?

First you should know what it really means to hold a share of Panacea Biotec Limited. And how you can make/lose money.

Speculation

The Price per Share of Panacea Biotec Limited is INR146.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Panacea Biotec Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Panacea Biotec Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR137.16. Based on the TTM, the Book Value Change Per Share is INR-0.93 per quarter. Based on the YOY, the Book Value Change Per Share is INR175.92 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Panacea Biotec Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps-0.070.0%-0.070.0%2.111.4%0.290.2%0.070.1%
Usd Book Value Change Per Share-0.010.0%-0.010.0%2.111.4%0.210.1%0.040.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%-0.010.0%2.111.4%0.210.1%0.040.0%
Usd Price Per Share1.30-1.30-1.78-1.78-1.80-
Price to Earnings Ratio-19.68--19.68-0.84-0.49--8.19-
Price-to-Total Gains Ratio-116.52--116.52-0.84--18.71--17.77-
Price to Book Ratio0.79-0.79-1.07-0.81-1.61-
Price-to-Total Gains Ratio-116.52--116.52-0.84--18.71--17.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.758
Number of shares568
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.21
Usd Total Gains Per Share-0.010.21
Gains per Quarter (568 shares)-6.34118.93
Gains per Year (568 shares)-25.38475.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-25-350476466
20-51-600951942
30-76-85014271418
40-102-110019031894
50-127-135023792370
60-152-160028542846
70-178-185033303322
80-203-210038063798
90-228-235042824274
100-254-260047574750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.08.00.020.0%8.011.00.042.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.08.00.020.0%9.010.00.047.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%8.00.011.042.1%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.08.00.020.0%9.010.00.047.4%

Fundamentals of Panacea Biotec Limited

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine. It also exports its products to approximately 36 countries, including the United States, Germany, Russian Federation, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Philippines, Sri Lanka, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. The company was incorporated in 1984 and is based in New Delhi, India.

Fundamental data was last updated by Penke on 2024-04-14 06:07:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Panacea Biotec Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Panacea Biotec Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • A Net Profit Margin of -7.3% means that ₹-0.07 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Panacea Biotec Limited:

  • The MRQ is -7.3%. The company is making a loss. -1
  • The TTM is -7.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-7.3%TTM-7.3%0.0%
TTM-7.3%YOY163.6%-170.9%
TTM-7.3%5Y20.9%-28.2%
5Y20.9%10Y4.0%+16.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.3%-207.2%+199.9%
TTM-7.3%-216.8%+209.5%
YOY163.6%-282.3%+445.9%
5Y20.9%-436.8%+457.7%
10Y4.0%-597.3%+601.3%
1.1.2. Return on Assets

Shows how efficient Panacea Biotec Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • -2.7% Return on Assets means that Panacea Biotec Limited generated ₹-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Panacea Biotec Limited:

  • The MRQ is -2.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.7%TTM-2.7%0.0%
TTM-2.7%YOY60.5%-63.1%
TTM-2.7%5Y6.8%-9.5%
5Y6.8%10Y1.4%+5.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.7%-13.3%+10.6%
TTM-2.7%-12.8%+10.1%
YOY60.5%-11.6%+72.1%
5Y6.8%-13.8%+20.6%
10Y1.4%-15.6%+17.0%
1.1.3. Return on Equity

Shows how efficient Panacea Biotec Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • -4.0% Return on Equity means Panacea Biotec Limited generated ₹-0.04 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Panacea Biotec Limited:

  • The MRQ is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-4.0%0.0%
TTM-4.0%YOY127.0%-131.0%
TTM-4.0%5Y7.2%-11.2%
5Y7.2%10Y-5.3%+12.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-16.9%+12.9%
TTM-4.0%-16.1%+12.1%
YOY127.0%-14.9%+141.9%
5Y7.2%-19.3%+26.5%
10Y-5.3%-20.1%+14.8%

1.2. Operating Efficiency of Panacea Biotec Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Panacea Biotec Limited is operating .

  • Measures how much profit Panacea Biotec Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • An Operating Margin of -18.6% means the company generated ₹-0.19  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Panacea Biotec Limited:

  • The MRQ is -18.6%. The company is operating very inefficient. -2
  • The TTM is -18.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-18.6%TTM-18.6%0.0%
TTM-18.6%YOY-7.1%-11.5%
TTM-18.6%5Y-8.2%-10.4%
5Y-8.2%10Y-3.3%-4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.6%-298.0%+279.4%
TTM-18.6%-238.5%+219.9%
YOY-7.1%-288.4%+281.3%
5Y-8.2%-486.2%+478.0%
10Y-3.3%-628.4%+625.1%
1.2.2. Operating Ratio

Measures how efficient Panacea Biotec Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.30 means that the operating costs are ₹1.30 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Panacea Biotec Limited:

  • The MRQ is 1.298. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.298. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.298TTM1.2980.000
TTM1.298YOY1.081+0.217
TTM1.2985Y1.095+0.204
5Y1.09510Y1.051+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2983.235-1.937
TTM1.2983.310-2.012
YOY1.0813.838-2.757
5Y1.0955.679-4.584
10Y1.0517.823-6.772

1.3. Liquidity of Panacea Biotec Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Panacea Biotec Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.71 means the company has ₹1.71 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Panacea Biotec Limited:

  • The MRQ is 1.713. The company is able to pay all its short-term debts. +1
  • The TTM is 1.713. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.713TTM1.7130.000
TTM1.713YOY1.296+0.416
TTM1.7135Y1.250+0.462
5Y1.25010Y1.044+0.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7133.863-2.150
TTM1.7134.169-2.456
YOY1.2965.337-4.041
5Y1.2506.122-4.872
10Y1.0446.434-5.390
1.3.2. Quick Ratio

Measures if Panacea Biotec Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • A Quick Ratio of 1.52 means the company can pay off ₹1.52 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Panacea Biotec Limited:

  • The MRQ is 1.519. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.519. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.519TTM1.5190.000
TTM1.519YOY1.413+0.106
TTM1.5195Y0.843+0.676
5Y0.84310Y0.552+0.292
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5193.504-1.985
TTM1.5193.991-2.472
YOY1.4135.371-3.958
5Y0.8436.088-5.245
10Y0.5526.395-5.843

1.4. Solvency of Panacea Biotec Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Panacea Biotec Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Panacea Biotec Limited to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that Panacea Biotec Limited assets are financed with 33.9% credit (debt) and the remaining percentage (100% - 33.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Panacea Biotec Limited:

  • The MRQ is 0.339. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.339. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.339TTM0.3390.000
TTM0.339YOY0.525-0.186
TTM0.3395Y0.734-0.394
5Y0.73410Y0.751-0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3390.339+0.000
TTM0.3390.337+0.002
YOY0.5250.271+0.254
5Y0.7340.368+0.366
10Y0.7510.388+0.363
1.4.2. Debt to Equity Ratio

Measures if Panacea Biotec Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • A Debt to Equity ratio of 51.1% means that company has ₹0.51 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Panacea Biotec Limited:

  • The MRQ is 0.511. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.511. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.511TTM0.5110.000
TTM0.511YOY1.104-0.593
TTM0.5115Y2.112-1.601
5Y2.11210Y2.746-0.634
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5110.392+0.119
TTM0.5110.403+0.108
YOY1.1040.335+0.769
5Y2.1120.427+1.685
10Y2.7460.461+2.285

2. Market Valuation of Panacea Biotec Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Panacea Biotec Limited generates.

  • Above 15 is considered overpriced but always compare Panacea Biotec Limited to the Biotechnology industry mean.
  • A PE ratio of -19.68 means the investor is paying ₹-19.68 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Panacea Biotec Limited:

  • The EOD is -26.587. Based on the earnings, the company is expensive. -2
  • The MRQ is -19.682. Based on the earnings, the company is expensive. -2
  • The TTM is -19.682. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-26.587MRQ-19.682-6.905
MRQ-19.682TTM-19.6820.000
TTM-19.682YOY0.842-20.524
TTM-19.6825Y0.490-20.172
5Y0.49010Y-8.188+8.678
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-26.587-2.300-24.287
MRQ-19.682-2.656-17.026
TTM-19.682-2.718-16.964
YOY0.842-4.145+4.987
5Y0.490-6.258+6.748
10Y-8.188-6.315-1.873
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Panacea Biotec Limited:

  • The EOD is -1.932. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.430. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.430. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.932MRQ-1.430-0.502
MRQ-1.430TTM-1.4300.000
TTM-1.430YOY-7.505+6.075
TTM-1.4305Y-0.365-1.065
5Y-0.36510Y20.926-21.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.932-2.974+1.042
MRQ-1.430-3.306+1.876
TTM-1.430-3.508+2.078
YOY-7.505-5.613-1.892
5Y-0.365-8.378+8.013
10Y20.926-8.873+29.799
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Panacea Biotec Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.79 means the investor is paying ₹0.79 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Panacea Biotec Limited:

  • The EOD is 1.068. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.791. Based on the equity, the company is cheap. +2
  • The TTM is 0.791. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.068MRQ0.791+0.277
MRQ0.791TTM0.7910.000
TTM0.791YOY1.073-0.283
TTM0.7915Y0.809-0.018
5Y0.80910Y1.607-0.798
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0681.914-0.846
MRQ0.7912.116-1.325
TTM0.7912.097-1.306
YOY1.0732.881-1.808
5Y0.8093.550-2.741
10Y1.6073.936-2.329
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Panacea Biotec Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.931-0.9310%175.917-101%17.449-105%3.381-128%
Book Value Per Share--137.159137.1590%138.090-1%65.219+110%67.641+103%
Current Ratio--1.7131.7130%1.296+32%1.250+37%1.044+64%
Debt To Asset Ratio--0.3390.3390%0.525-35%0.734-54%0.751-55%
Debt To Equity Ratio--0.5110.5110%1.104-54%2.112-76%2.746-81%
Dividend Per Share----0%-0%-0%-0%
Eps---5.510-5.5100%175.979-103%24.160-123%6.114-190%
Free Cash Flow Per Share---75.821-75.8210%-19.746-74%-14.290-81%-2.291-97%
Free Cash Flow To Equity Per Share---78.822-78.8220%-211.720+169%-55.163-30%-29.208-63%
Gross Profit Margin--1.6861.6860%0.955+76%1.076+57%1.321+28%
Intrinsic Value_10Y_max---83.298--------
Intrinsic Value_10Y_min---1059.398--------
Intrinsic Value_1Y_max---3.604--------
Intrinsic Value_1Y_min---47.612--------
Intrinsic Value_3Y_max---14.444--------
Intrinsic Value_3Y_min---194.612--------
Intrinsic Value_5Y_max---29.642--------
Intrinsic Value_5Y_min---396.989--------
Market Cap8973227550.000+26%6642643403.7006642643403.7000%9077360557.200-27%9100023333.220-27%9179649303.020-28%
Net Profit Margin---0.073-0.0730%1.636-104%0.209-135%0.040-285%
Operating Margin---0.186-0.1860%-0.071-62%-0.082-56%-0.033-82%
Operating Ratio--1.2981.2980%1.081+20%1.095+19%1.051+23%
Pb Ratio1.068+26%0.7910.7910%1.073-26%0.809-2%1.607-51%
Pe Ratio-26.587-35%-19.682-19.6820%0.842-2437%0.490-4116%-8.188-58%
Price Per Share146.500+26%108.450108.4500%148.200-27%148.570-27%149.870-28%
Price To Free Cash Flow Ratio-1.932-35%-1.430-1.4300%-7.505+425%-0.365-74%20.926-107%
Price To Total Gains Ratio-157.398-35%-116.517-116.5170%0.842-13931%-18.706-84%-17.770-85%
Quick Ratio--1.5191.5190%1.413+7%0.843+80%0.552+175%
Return On Assets---0.027-0.0270%0.605-104%0.068-139%0.014-295%
Return On Equity---0.040-0.0400%1.270-103%0.072-155%-0.053+33%
Total Gains Per Share---0.931-0.9310%175.917-101%17.449-105%3.381-128%
Usd Book Value--100813200.000100813200.0000%101497320.000-1%47936760.000+110%49717080.000+103%
Usd Book Value Change Per Share---0.011-0.0110%2.111-101%0.209-105%0.041-128%
Usd Book Value Per Share--1.6461.6460%1.657-1%0.783+110%0.812+103%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.066-0.0660%2.112-103%0.290-123%0.073-190%
Usd Free Cash Flow---55729200.000-55729200.0000%-14513400.000-74%-10503360.000-81%-1683636.000-97%
Usd Free Cash Flow Per Share---0.910-0.9100%-0.237-74%-0.171-81%-0.027-97%
Usd Free Cash Flow To Equity Per Share---0.946-0.9460%-2.541+169%-0.662-30%-0.350-63%
Usd Market Cap107678730.600+26%79711720.84479711720.8440%108928326.686-27%109200279.999-27%110155791.636-28%
Usd Price Per Share1.758+26%1.3011.3010%1.778-27%1.783-27%1.798-28%
Usd Profit---4050000.000-4050000.0000%129397800.000-103%17767896.000-123%4355304.000-193%
Usd Revenue--55194000.00055194000.0000%79106760.000-30%65432256.000-16%68553768.000-19%
Usd Total Gains Per Share---0.011-0.0110%2.111-101%0.209-105%0.041-128%
 EOD+5 -3MRQTTM+0 -0YOY+10 -245Y+12 -2210Y+13 -21

3.2. Fundamental Score

Let's check the fundamental score of Panacea Biotec Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-26.587
Price to Book Ratio (EOD)Between0-11.068
Net Profit Margin (MRQ)Greater than0-0.073
Operating Margin (MRQ)Greater than0-0.186
Quick Ratio (MRQ)Greater than11.519
Current Ratio (MRQ)Greater than11.713
Debt to Asset Ratio (MRQ)Less than10.339
Debt to Equity Ratio (MRQ)Less than10.511
Return on Equity (MRQ)Greater than0.15-0.040
Return on Assets (MRQ)Greater than0.05-0.027
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Panacea Biotec Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.723
Ma 20Greater thanMa 50137.923
Ma 50Greater thanMa 100144.107
Ma 100Greater thanMa 200157.124
OpenGreater thanClose142.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Minority Interest  -30,090-290-30,380380-30,00029,810-1905,2705,080



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets12,711,600
Total Liabilities4,310,500
Total Stockholder Equity8,436,100
 As reported
Total Liabilities 4,310,500
Total Stockholder Equity+ 8,436,100
Total Assets = 12,711,600

Assets

Total Assets12,711,600
Total Current Assets5,683,100
Long-term Assets7,028,500
Total Current Assets
Cash And Cash Equivalents 398,500
Short-term Investments 2,020,500
Net Receivables 600,920
Inventory 2,020,900
Other Current Assets 566,500
Total Current Assets  (as reported)5,683,100
Total Current Assets  (calculated)5,607,320
+/- 75,780
Long-term Assets
Property Plant Equipment 6,163,400
Intangible Assets 259,400
Other Assets 493,000
Long-term Assets  (as reported)7,028,500
Long-term Assets  (calculated)6,915,800
+/- 112,700

Liabilities & Shareholders' Equity

Total Current Liabilities3,318,300
Long-term Liabilities992,200
Total Stockholder Equity8,436,100
Total Current Liabilities
Short-term Debt 600
Short Long Term Debt 600
Accounts payable 1,773,200
Other Current Liabilities 952,900
Total Current Liabilities  (as reported)3,318,300
Total Current Liabilities  (calculated)2,727,300
+/- 591,000
Long-term Liabilities
Long term Debt Total 201,600
Other Liabilities 790,570
Long-term Liabilities  (as reported)992,200
Long-term Liabilities  (calculated)992,170
+/- 30
Total Stockholder Equity
Common Stock61,300
Retained Earnings 7,898,520
Capital Surplus 919,400
Other Stockholders Equity -535,270
Total Stockholder Equity (as reported)8,436,100
Total Stockholder Equity (calculated)8,343,950
+/- 92,150
Other
Capital Stock61,300
Cash And Equivalents420
Cash and Short Term Investments 2,419,000
Common Stock Shares Outstanding 61,251
Current Deferred Revenue591,600
Liabilities and Stockholders Equity 12,711,600
Net Debt -196,300
Net Invested Capital 8,638,300
Net Tangible Assets 8,066,190
Net Working Capital 2,364,800
Property Plant and Equipment Gross 6,163,400
Short Long Term Debt Total 202,200



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-31
> Total Assets 
4,710,638
10,104,910
10,324,365
12,998,752
17,114,991
16,857,703
17,338,500
20,056,700
18,394,600
19,433,500
19,304,700
18,544,100
18,620,700
16,075,550
13,755,200
13,903,000
11,788,160
17,825,050
12,711,600
12,711,60017,825,05011,788,16013,903,00013,755,20016,075,55018,620,70018,544,10019,304,70019,433,50018,394,60020,056,70017,338,50016,857,70317,114,99112,998,75210,324,36510,104,9104,710,638
   > Total Current Assets 
3,290,693
7,733,551
6,128,457
6,115,547
7,724,713
7,495,105
8,550,600
5,245,000
4,337,500
3,810,200
5,257,200
5,485,900
6,106,800
5,603,450
5,078,860
6,832,680
5,109,720
10,405,500
5,683,100
5,683,10010,405,5005,109,7206,832,6805,078,8605,603,4506,106,8005,485,9005,257,2003,810,2004,337,5005,245,0008,550,6007,495,1057,724,7136,115,5476,128,4577,733,5513,290,693
       Cash And Cash Equivalents 
99,679
4,448,970
1,656,733
1,546,803
748,423
470,449
522,400
155,100
392,300
247,800
524,000
229,300
239,000
164,370
144,660
402,180
520,790
503,500
398,500
398,500503,500520,790402,180144,660164,370239,000229,300524,000247,800392,300155,100522,400470,449748,4231,546,8031,656,7334,448,97099,679
       Short-term Investments 
464,150
666,147
1,437,600
932,108
1,233,020
1,340,792
1,091,300
16,000
529,300
300
49,800
35,200
2,700
28,080
8,220
149,880
467,550
5,012,780
2,020,500
2,020,5005,012,780467,550149,8808,22028,0802,70035,20049,800300529,30016,0001,091,3001,340,7921,233,020932,1081,437,600666,147464,150
       Net Receivables 
0
0
0
0
0
0
0
0
0
1,010,100
1,053,300
1,233,710
1,575,950
1,757,110
3,958,410
685,190
846,840
816,560
600,920
600,920816,560846,840685,1903,958,4101,757,1101,575,9501,233,7101,053,3001,010,100000000000
       Inventory 
1,933,537
1,817,127
2,091,925
2,145,753
4,513,037
4,576,717
4,106,300
3,852,600
2,679,400
2,198,100
3,102,200
3,052,400
3,077,800
3,342,060
814,270
1,476,910
1,741,370
2,127,220
2,020,900
2,020,9002,127,2201,741,3701,476,910814,2703,342,0603,077,8003,052,4003,102,2002,198,1002,679,4003,852,6004,106,3004,576,7174,513,0372,145,7532,091,9251,817,1271,933,537
       Other Current Assets 
793,327
801,308
942,198
1,490,881
1,230,233
1,107,148
2,830,600
1,221,300
736,500
1,364,000
1,581,200
2,169,000
2,787,300
2,068,940
153,300
4,149,450
647,100
613,100
566,500
566,500613,100647,1004,149,450153,3002,068,9402,787,3002,169,0001,581,2001,364,000736,5001,221,3002,830,6001,107,1481,230,2331,490,881942,198801,308793,327
   > Long-term Assets 
1,419,945
2,371,359
4,195,908
6,883,206
9,390,278
9,362,598
8,787,900
14,811,700
14,057,100
15,623,300
14,047,500
13,058,200
12,513,900
10,472,100
8,676,340
7,070,290
6,678,440
7,419,550
7,028,500
7,028,5007,419,5506,678,4407,070,2908,676,34010,472,10012,513,90013,058,20014,047,50015,623,30014,057,10014,811,7008,787,9009,362,5989,390,2786,883,2064,195,9082,371,3591,419,945
       Property Plant Equipment 
1,311,408
2,233,167
3,864,639
6,357,017
8,338,724
8,341,825
8,059,800
11,985,900
12,298,000
13,983,100
12,597,200
12,026,700
11,539,000
9,503,950
8,115,000
6,650,300
6,278,940
5,927,190
6,163,400
6,163,4005,927,1906,278,9406,650,3008,115,0009,503,95011,539,00012,026,70012,597,20013,983,10012,298,00011,985,9008,059,8008,341,8258,338,7246,357,0173,864,6392,233,1671,311,408
       Goodwill 
19,564
19,564
176,755
176,755
36,249
55,641
34,700
0
0
53,100
67,200
8,960
8,960
8,960
0
0
0
0
0
000008,9608,9608,96067,20053,1000034,70055,64136,249176,755176,75519,56419,564
       Long Term Investments 
0
0
0
0
0
0
0
0
0
163,200
102,800
57,500
70,110
52,470
53,290
0
0
0
0
000053,29052,47070,11057,500102,800163,200000000000
       Intangible Assets 
74,085
108,882
147,392
191,301
214,584
236,479
126,400
873,400
0
195,400
168,100
230,110
285,640
376,050
165,700
163,630
152,210
138,240
259,400
259,400138,240152,210163,630165,700376,050285,640230,110168,100195,4000873,400126,400236,479214,584191,301147,392108,88274,085
       Other Assets 
0
0
0
0
0
0
0
0
0
1,310,600
1,112,200
207,840
651,770
558,240
356,130
30
254,270
523,400
493,000
493,000523,400254,27030356,130558,240651,770207,8401,112,2001,310,600000000000
> Total Liabilities 
2,590,475
7,647,998
4,962,207
6,037,670
10,918,520
9,802,077
10,785,800
11,239,500
12,064,200
14,251,500
14,557,600
14,047,200
14,646,800
13,018,200
10,281,320
11,945,510
14,105,090
9,366,940
4,310,500
4,310,5009,366,94014,105,09011,945,51010,281,32013,018,20014,646,80014,047,20014,557,60014,251,50012,064,20011,239,50010,785,8009,802,07710,918,5206,037,6704,962,2077,647,9982,590,475
   > Total Current Liabilities 
843,659
1,539,065
2,449,791
1,456,248
3,553,635
2,020,839
1,375,800
5,189,000
5,099,600
8,365,300
7,060,300
4,748,000
5,995,400
6,910,240
9,382,610
4,552,080
4,256,630
8,027,680
3,318,300
3,318,3008,027,6804,256,6304,552,0809,382,6106,910,2405,995,4004,748,0007,060,3008,365,3005,099,6005,189,0001,375,8002,020,8393,553,6351,456,2482,449,7911,539,065843,659
       Short-term Debt 
0
0
0
0
0
0
0
2,495,400
2,740,000
3,206,700
2,958,400
1,918,200
1,976,300
3,700,380
6,003,730
1,290,590
844,460
520
600
600520844,4601,290,5906,003,7303,700,3801,976,3001,918,2002,958,4003,206,7002,740,0002,495,4000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
10,609,400
760,700
295,300
1,976,300
3,700,380
6,003,730
1,290,590
844,460
500
600
600500844,4601,290,5906,003,7303,700,3801,976,300295,300760,70010,609,400000000000
       Accounts payable 
549,917
879,593
1,251,198
1,096,709
1,624,243
1,474,964
973,800
0
1,756,900
2,521,100
2,091,300
1,858,700
2,360,600
34,710
2,697,100
1,988,520
2,219,440
2,597,770
1,773,200
1,773,2002,597,7702,219,4401,988,5202,697,10034,7102,360,6001,858,7002,091,3002,521,1001,756,9000973,8001,474,9641,624,2431,096,7091,251,198879,593549,917
       Other Current Liabilities 
293,742
659,472
1,198,593
359,540
1,929,392
545,875
402,000
2,693,600
602,700
2,637,500
2,010,600
971,100
1,658,500
3,175,070
43,200
43,530
128,890
3,203,140
952,900
952,9003,203,140128,89043,53043,2003,175,0701,658,500971,1002,010,6002,637,500602,7002,693,600402,000545,8751,929,392359,5401,198,593659,472293,742
   > Long-term Liabilities 
1,746,816
6,108,933
2,512,415
4,581,421
7,364,885
7,781,238
9,410,000
6,050,500
6,964,600
5,886,200
7,497,300
9,299,200
8,651,400
6,107,960
898,710
7,393,430
9,848,460
1,339,260
992,200
992,2001,339,2609,848,4607,393,430898,7106,107,9608,651,4009,299,2007,497,3005,886,2006,964,6006,050,5009,410,0007,781,2387,364,8854,581,4212,512,4156,108,9331,746,816
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
7,857,110
7,140,610
5,707,080
461,220
6,131,280
7,350,800
341,000
201,600
201,600341,0007,350,8006,131,280461,2205,707,0807,140,6107,857,11000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
139,800
128,700
150,700
342,200
400,880
437,490
1,294,750
2,497,660
998,230
790,570
790,570998,2302,497,6601,294,750437,490400,880342,200150,700128,700139,800000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
248,600
165,300
82,300
35,550
27,570
13,780
9,150
12,500
5,880
106,110
106,1105,88012,5009,15013,78027,57035,55082,300165,300248,600000000000
> Total Stockholder Equity
2,120,162
2,456,912
5,362,159
6,961,083
6,167,502
7,007,286
6,488,700
8,751,200
6,256,900
5,127,200
4,712,900
4,486,100
3,973,900
3,086,850
3,503,970
1,987,870
-2,286,930
8,487,920
8,436,100
8,436,1008,487,920-2,286,9301,987,8703,503,9703,086,8503,973,9004,486,1004,712,9005,127,2006,256,9008,751,2006,488,7007,007,2866,167,5026,961,0835,362,1592,456,9122,120,162
   Common Stock
961,518
961,518
65,774
66,786
66,786
66,843
61,300
61,300
61,300
61,300
224,300
224,300
224,300
61,250
61,250
61,250
61,250
61,250
61,300
61,30061,25061,25061,25061,25061,250224,300224,300224,30061,30061,30061,30061,30066,84366,78666,78665,774961,518961,518
   Retained Earnings 
1,158,644
1,495,394
5,296,384
6,894,296
6,100,716
6,940,443
0
2,063,500
-287,200
-1,408,500
-2,297,100
-2,480,000
-3,124,600
513,390
884,150
-1,077,090
-2,540,080
8,237,780
7,898,520
7,898,5208,237,780-2,540,080-1,077,090884,150513,390-3,124,600-2,480,000-2,297,100-1,408,500-287,2002,063,50006,940,4436,100,7166,894,2965,296,3841,495,3941,158,644
   Accumulated Other Comprehensive Income 
-561,206
-739,754
-1,103,380
-1,561,222
-2,213,043
-2,822,828
0
-4,120,100
-4,962,000
-3,655,200
-4,212,300
-4,706,800
-5,271,700
-5,750,950
-5,058,890
-5,352,110
794,990
525,040
795,010
795,010525,040794,990-5,352,110-5,058,890-5,750,950-5,271,700-4,706,800-4,212,300-3,655,200-4,962,000-4,120,1000-2,822,828-2,213,043-1,561,222-1,103,380-739,754-561,206
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
919,400
919,400
919,400
919,400
919,400
919,400
919,400
919,400
919,400919,400919,400919,400919,400919,400919,400919,40000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
561,206
739,754
1,103,380
1,561,222
2,213,043
2,822,828
6,427,400
10,746,500
11,444,800
10,129,600
10,998,000
11,448,600
12,145,900
8,263,160
7,617,460
8,137,890
-819,630
-552,690
-535,270
-535,270-552,690-819,6308,137,8907,617,4608,263,16012,145,90011,448,60010,998,00010,129,60011,444,80010,746,5006,427,4002,822,8282,213,0431,561,2221,103,380739,754561,206



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue4,599,500
Cost of Revenue-2,526,600
Gross Profit2,072,9002,072,900
 
Operating Income (+$)
Gross Profit2,072,900
Operating Expense-3,443,700
Operating Income-1,027,390-1,370,800
 
Operating Expense (+$)
Research Development328,200
Selling General Administrative158,400
Selling And Marketing Expenses231,400
Operating Expense3,443,700718,000
 
Net Interest Income (+$)
Interest Income44,400
Interest Expense-44,400
Other Finance Cost-44,400
Net Interest Income-44,400
 
Pretax Income (+$)
Operating Income-1,027,390
Net Interest Income-44,400
Other Non-Operating Income Expenses0
Income Before Tax (EBT)128,000-2,182,830
EBIT - interestExpense = -898,600
128,000
-293,100
Interest Expense44,400
Earnings Before Interest and Taxes (EBIT)-854,200172,400
Earnings Before Interest and Taxes (EBITDA)-463,000
 
After tax Income (+$)
Income Before Tax128,000
Tax Provision-465,500
Net Income From Continuing Ops-337,500-337,500
Net Income-337,500
Net Income Applicable To Common Shares-337,500
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,970,300
Total Other Income/Expenses Net1,155,44044,400
 

Technical Analysis of Panacea Biotec Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Panacea Biotec Limited. The general trend of Panacea Biotec Limited is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Panacea Biotec Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Panacea Biotec Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 161.25 < 166.70 < 169.70.

The bearish price targets are: 121.10 > 120.30 > 116.00.

Tweet this
Panacea Biotec Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Panacea Biotec Limited. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Panacea Biotec Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Panacea Biotec Limited. The current macd is -0.28073203.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Panacea Biotec Limited price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Panacea Biotec Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Panacea Biotec Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Panacea Biotec Limited Daily Moving Average Convergence/Divergence (MACD) ChartPanacea Biotec Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Panacea Biotec Limited. The current adx is 21.09.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Panacea Biotec Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Panacea Biotec Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Panacea Biotec Limited. The current sar is 153.52.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Panacea Biotec Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Panacea Biotec Limited. The current rsi is 57.72. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Panacea Biotec Limited Daily Relative Strength Index (RSI) ChartPanacea Biotec Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Panacea Biotec Limited. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Panacea Biotec Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Panacea Biotec Limited Daily Stochastic Oscillator ChartPanacea Biotec Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Panacea Biotec Limited. The current cci is 92.00.

Panacea Biotec Limited Daily Commodity Channel Index (CCI) ChartPanacea Biotec Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Panacea Biotec Limited. The current cmo is 29.48.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Panacea Biotec Limited Daily Chande Momentum Oscillator (CMO) ChartPanacea Biotec Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Panacea Biotec Limited. The current willr is -55.55555556.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Panacea Biotec Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Panacea Biotec Limited Daily Williams %R ChartPanacea Biotec Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Panacea Biotec Limited.

Panacea Biotec Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Panacea Biotec Limited. The current atr is 6.55324105.

Panacea Biotec Limited Daily Average True Range (ATR) ChartPanacea Biotec Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Panacea Biotec Limited. The current obv is 16,037,516.

Panacea Biotec Limited Daily On-Balance Volume (OBV) ChartPanacea Biotec Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Panacea Biotec Limited. The current mfi is 75.32.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Panacea Biotec Limited Daily Money Flow Index (MFI) ChartPanacea Biotec Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Panacea Biotec Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Panacea Biotec Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Panacea Biotec Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.723
Ma 20Greater thanMa 50137.923
Ma 50Greater thanMa 100144.107
Ma 100Greater thanMa 200157.124
OpenGreater thanClose142.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Panacea Biotec Limited with someone you think should read this too:
  • Are you bullish or bearish on Panacea Biotec Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Panacea Biotec Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Panacea Biotec Limited

I send you an email if I find something interesting about Panacea Biotec Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Panacea Biotec Limited.

Receive notifications about Panacea Biotec Limited in your mailbox!